CD274 and neoplasm: Preclinical studies by Zhang et al., were able to show [148] that in a preclinical model significant tumor growth inhibition with combined treatment with PARPi, olaparib, radiotherapy, and anti-PD-L1 antibody which was significant relative to doublet therapy with olaparib-radiation or anti-PD-L1-radiation, and associated with a 20% complete response rate.